658 related articles for article (PubMed ID: 28441895)
1. Ketamine's dose-related effects on anxiety symptoms in patients with treatment refractory anxiety disorders.
Glue P; Medlicott NJ; Harland S; Neehoff S; Anderson-Fahey B; Le Nedelec M; Gray A; McNaughton N
J Psychopharmacol; 2017 Oct; 31(10):1302-1305. PubMed ID: 28441895
[TBL] [Abstract][Full Text] [Related]
2. Effects of ketamine in patients with treatment-refractory generalized anxiety and social anxiety disorders: Exploratory double-blind psychoactive-controlled replication study.
Glue P; Neehoff S; Sabadel A; Broughton L; Le Nedelec M; Shadli S; McNaughton N; Medlicott NJ
J Psychopharmacol; 2020 Mar; 34(3):267-272. PubMed ID: 31526207
[TBL] [Abstract][Full Text] [Related]
3. Ketamine for treatment-resistant major depressive disorder: Double-blind active-controlled crossover study.
Glue P; Neehoff S; Beaglehole B; Shadli S; McNaughton N; Hughes-Medlicott NJ
J Psychopharmacol; 2024 Feb; 38(2):162-167. PubMed ID: 38293803
[TBL] [Abstract][Full Text] [Related]
4. Ketamine's antidepressant efficacy is extended for at least four weeks in subjects with a family history of an alcohol use disorder.
Niciu MJ; Luckenbaugh DA; Ionescu DF; Richards EM; Vande Voort JL; Ballard ED; Brutsche NE; Furey ML; Zarate CA
Int J Neuropsychopharmacol; 2014 Oct; 18(1):. PubMed ID: 25539512
[TBL] [Abstract][Full Text] [Related]
5. Ketamine administration in depressive disorders: a systematic review and meta-analysis.
Fond G; Loundou A; Rabu C; Macgregor A; Lançon C; Brittner M; Micoulaud-Franchi JA; Richieri R; Courtet P; Abbar M; Roger M; Leboyer M; Boyer L
Psychopharmacology (Berl); 2014 Sep; 231(18):3663-76. PubMed ID: 25038867
[TBL] [Abstract][Full Text] [Related]
6. A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.
Naughton M; Clarke G; O'Leary OF; Cryan JF; Dinan TG
J Affect Disord; 2014 Mar; 156():24-35. PubMed ID: 24388038
[TBL] [Abstract][Full Text] [Related]
7. Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine.
Ionescu DF; Luckenbaugh DA; Niciu MJ; Richards EM; Slonena EE; Vande Voort JL; Brutsche NE; Zarate CA
J Clin Psychiatry; 2014 Sep; 75(9):e932-8. PubMed ID: 25295436
[TBL] [Abstract][Full Text] [Related]
8. Two cases of delayed-onset suicidal ideation, dysphoria and anxiety after ketamine infusion in patients with obsessive-compulsive disorder and a history of major depressive disorder.
Niciu MJ; Grunschel BD; Corlett PR; Pittenger C; Bloch MH
J Psychopharmacol; 2013 Jul; 27(7):651-4. PubMed ID: 23676198
[TBL] [Abstract][Full Text] [Related]
9. Ketamine for Treatment-Resistant Depression: a New Advocate.
Pérez-Esparza R
Rev Invest Clin; 2018; 70(2):65-7. PubMed ID: 29718013
[TBL] [Abstract][Full Text] [Related]
10. Ketamine: Leading us into the future for development of antidepressants.
Carreno FR; Lodge DJ; Frazer A
Behav Brain Res; 2020 Apr; 383():112532. PubMed ID: 32023492
[TBL] [Abstract][Full Text] [Related]
11. Anxiety during ketamine infusions is associated with negative treatment responses in major depressive disorder.
Aust S; Gärtner M; Basso L; Otte C; Wingenfeld K; Chae WR; Heuser-Collier I; Regen F; Cosma NC; van Hall F; Grimm S; Bajbouj M
Eur Neuropsychopharmacol; 2019 Apr; 29(4):529-538. PubMed ID: 30772118
[TBL] [Abstract][Full Text] [Related]
12. A Randomized Controlled Trial of Repeated Ketamine Administration for Chronic Posttraumatic Stress Disorder.
Feder A; Costi S; Rutter SB; Collins AB; Govindarajulu U; Jha MK; Horn SR; Kautz M; Corniquel M; Collins KA; Bevilacqua L; Glasgow AM; Brallier J; Pietrzak RH; Murrough JW; Charney DS
Am J Psychiatry; 2021 Feb; 178(2):193-202. PubMed ID: 33397139
[TBL] [Abstract][Full Text] [Related]
13. Efficacy, Safety, and Durability of Repeated Ketamine Infusions for Comorbid Posttraumatic Stress Disorder and Treatment-Resistant Depression.
Albott CS; Lim KO; Forbes MK; Erbes C; Tye SJ; Grabowski JG; Thuras P; Batres-Y-Carr TM; Wels J; Shiroma PR
J Clin Psychiatry; 2018; 79(3):. PubMed ID: 29727073
[TBL] [Abstract][Full Text] [Related]
14. Two cellular hypotheses explaining the initiation of ketamine's antidepressant actions: Direct inhibition and disinhibition.
Miller OH; Moran JT; Hall BJ
Neuropharmacology; 2016 Jan; 100():17-26. PubMed ID: 26211972
[TBL] [Abstract][Full Text] [Related]
15. The rapid-onset antidepressant effect of ketamine: More surprises?
Raffa RB; Pergolizzi JV; Taylor R;
J Clin Pharm Ther; 2018 Apr; 43(2):308-311. PubMed ID: 29178131
[TBL] [Abstract][Full Text] [Related]
16. Continuation phase intravenous ketamine in adults with treatment-resistant depression.
Vande Voort JL; Morgan RJ; Kung S; Rasmussen KG; Rico J; Palmer BA; Schak KM; Tye SJ; Ritter MJ; Frye MA; Bobo WV
J Affect Disord; 2016 Dec; 206():300-304. PubMed ID: 27656788
[TBL] [Abstract][Full Text] [Related]
17. Plasma metabolomic profiling of a ketamine and placebo crossover trial of major depressive disorder and healthy control subjects.
Moaddel R; Shardell M; Khadeer M; Lovett J; Kadriu B; Ravichandran S; Morris PJ; Yuan P; Thomas CJ; Gould TD; Ferrucci L; Zarate CA
Psychopharmacology (Berl); 2018 Oct; 235(10):3017-3030. PubMed ID: 30116859
[TBL] [Abstract][Full Text] [Related]
18. The effectiveness of intravenous ketamine in adults with treatment-resistant major depressive disorder and bipolar disorder presenting with prominent anxiety: Results from the Canadian Rapid Treatment Center of Excellence.
McIntyre RS; Rodrigues NB; Lipsitz O; Nasri F; Gill H; Lui LM; Subramaniapillai M; Kratiuk K; Teopiz K; Ho R; Lee Y; Mansur RB; Rosenblat JD
J Psychopharmacol; 2021 Feb; 35(2):128-136. PubMed ID: 33040665
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of maintenance ketamine treatment in patients with treatment-refractory generalised anxiety and social anxiety disorders.
Glue P; Neehoff SM; Medlicott NJ; Gray A; Kibby G; McNaughton N
J Psychopharmacol; 2018 Jun; 32(6):663-667. PubMed ID: 29561204
[TBL] [Abstract][Full Text] [Related]
20. Overlap in the neural circuitry and molecular mechanisms underlying ketamine abuse and its use as an antidepressant.
Kokane SS; Armant RJ; Bolaños-Guzmán CA; Perrotti LI
Behav Brain Res; 2020 Apr; 384():112548. PubMed ID: 32061748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
